Benjamin L Wolozin

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi Re-assessing the relationship between cholesterol, statins and Alzheimer's disease
    B Wolozin
    Department of Pharmacology, Boston University School of Medicine, MA 02118, USA
    Acta Neurol Scand Suppl 185:63-70. 2006
  2. pmc Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis
    Nien Chen Li
    Center for the Assessment of Pharmaceutical Practices and Pharmaceutical Assessment, Management and Policy Program, Department of Health Policy and Management, Boston University School of Public Health, Boston, MA 02118 2526, USA
    BMJ 340:b5465. 2010
  3. pmc Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue
    Liqun Liu-Yesucevitz
    Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts, United States of America
    PLoS ONE 5:e13250. 2010
  4. pmc Regulated protein aggregation: stress granules and neurodegeneration
    Benjamin Wolozin
    Departments of Pharmacology and Neurology, Boston University School of Medicine, 72 East Concord St, R614, Boston, MA 02118 2526, USA
    Mol Neurodegener 7:56. 2012
  5. pmc Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design
    Benjamin Wolozin
    Departments of Pharmacology and Neurology, Boston University School of Medicine, 715 Albany Street, Room R614, Boston, MA 02118 2526, USA
    Alzheimers Res Ther 4:3. 2012
  6. pmc Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein
    Celina V Zerbinatti
    Department of Pharmacology, Boston University School of Medicine, Boston, MA, 02118, USA
    Mol Neurodegener 3:5. 2008
  7. pmc Investigating convergent actions of genes linked to familial Parkinson's disease
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, Boston, Mass 02118 2526, USA
    Neurodegener Dis 5:182-5. 2008
  8. pmc Interventions for heart disease and their effects on Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, Boston, MA 02118 2526, USA
    Neurol Res 28:630-6. 2006
  9. ncbi Cholesterol, statins and dementia
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, L 603, Boston, MA 02118 2526, USA
    Curr Opin Lipidol 15:667-72. 2004
  10. pmc Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
    Benjamin Wolozin
    Boston University School of Medicine, Boston, MA, USA
    BMC Med 5:20. 2007

Research Grants

  1. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2001
  2. LRRK2 and Neurodegeneration
    Benjamin Wolozin; Fiscal Year: 2009
  3. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin L Wolozin; Fiscal Year: 2010
  4. LRRK2 and Neurodegeneration
    Benjamin L Wolozin; Fiscal Year: 2010
  5. LRRK2 and Neurodegeneration
    Benjamin Wolozin; Fiscal Year: 2009
  6. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin Wolozin; Fiscal Year: 2009
  7. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin Wolozin; Fiscal Year: 2007
  8. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin Wolozin; Fiscal Year: 2006
  9. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2004
  10. Regulation of APP Processing by Presenilins
    Benjamin Wolozin; Fiscal Year: 2004

Collaborators

Detail Information

Publications19

  1. ncbi Re-assessing the relationship between cholesterol, statins and Alzheimer's disease
    B Wolozin
    Department of Pharmacology, Boston University School of Medicine, MA 02118, USA
    Acta Neurol Scand Suppl 185:63-70. 2006
    ..These results suggest that the primary action of statins in humans with AD might be to reduce inflammation rather than decrease Abeta load...
  2. pmc Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis
    Nien Chen Li
    Center for the Assessment of Pharmaceutical Practices and Pharmaceutical Assessment, Management and Policy Program, Department of Health Policy and Management, Boston University School of Public Health, Boston, MA 02118 2526, USA
    BMJ 340:b5465. 2010
    ..To investigate whether angiotensin receptor blockers protect against Alzheimer's disease and dementia or reduce the progression of both diseases...
  3. pmc Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue
    Liqun Liu-Yesucevitz
    Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts, United States of America
    PLoS ONE 5:e13250. 2010
    ..These data provide support for accumulating evidence that TDP-43 participates in the SG pathway...
  4. pmc Regulated protein aggregation: stress granules and neurodegeneration
    Benjamin Wolozin
    Departments of Pharmacology and Neurology, Boston University School of Medicine, 72 East Concord St, R614, Boston, MA 02118 2526, USA
    Mol Neurodegener 7:56. 2012
    ..The reversibility of the stress granule pathway also offers novel opportunities to stimulate endogenous biochemical pathways to disaggregate these pathological stress granules, and perhaps delay the progression of disease...
  5. pmc Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design
    Benjamin Wolozin
    Departments of Pharmacology and Neurology, Boston University School of Medicine, 715 Albany Street, Room R614, Boston, MA 02118 2526, USA
    Alzheimers Res Ther 4:3. 2012
    ..Successful therapy of subjects with overt dementia might require approaches targeting all four pathophysiological domains...
  6. pmc Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein
    Celina V Zerbinatti
    Department of Pharmacology, Boston University School of Medicine, Boston, MA, 02118, USA
    Mol Neurodegener 3:5. 2008
    ....
  7. pmc Investigating convergent actions of genes linked to familial Parkinson's disease
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, Boston, Mass 02118 2526, USA
    Neurodegener Dis 5:182-5. 2008
    ..Mutations in LRRK2 are among the most frequent genetic changes identified in Parkinson's disease (PD), but how LRRK2 contributes to the pathophysiology of PD is not known...
  8. pmc Interventions for heart disease and their effects on Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, Boston, MA 02118 2526, USA
    Neurol Res 28:630-6. 2006
    ..To review the contributions of cardiovascular disease to Alzheimer's disease and vascular dementia...
  9. ncbi Cholesterol, statins and dementia
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, L 603, Boston, MA 02118 2526, USA
    Curr Opin Lipidol 15:667-72. 2004
    ..Although the genetics and cell biology continue to support the link between cholesterol and Alzheimer's disease, recent clinical studies suggest that the animal studies might not directly translate to clinical studies in humans...
  10. pmc Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
    Benjamin Wolozin
    Boston University School of Medicine, Boston, MA, USA
    BMC Med 5:20. 2007
    ..We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease...
  11. pmc MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2
    Cindy H Hsu
    Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118 2526, USA
    J Neurochem 112:1593-604. 2010
    ..These results were confirmed by deletion of sek-1 in C. elegans. These data demonstrate that MKKs and LRRK2 function in similar biological pathways, and support a role for LRRK2 in modulating the cellular stress response...
  12. ncbi Cholesterol and the biology of Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA
    Neuron 41:7-10. 2004
    ..The ability of cholesterol to modulate Abeta production suggests opportunities for therapeutic intervention, although the functional significance underlying the connection between cholesterol and Abeta remains to be investigated...
  13. pmc LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans
    Shamol Saha
    Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Neurosci 29:9210-8. 2009
    ....
  14. pmc Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans
    Rina Ved
    Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118 2526, USA
    J Biol Chem 280:42655-68. 2005
    ..These results show that diverse PD-related genetic modifications disrupt the mitochondrial function in C. elegans, and they raise the possibility that mitochondrial disruption is a pathway shared in common by many types of familial PD...
  15. ncbi The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Rm 3634, 2160 South First Ave, Maywood, IL 60153, USA
    CNS Drug Rev 10:127-46. 2004
    ..These lines of evidence raise the possibility that genetic abnormalities in cholesterol metabolism might contribute to the pathophysiology of AD...
  16. pmc The spectrum of disease in chronic traumatic encephalopathy
    Ann C McKee
    United States Department of Veterans Affairs, VA Boston Healthcare System, Boston, MA 02130, USA
    Brain 136:43-64. 2013
    ....
  17. ncbi Pathological proteins in Parkinson's disease: focus on the proteasome
    Heather Snyder
    Boston University School of Medicine, 715 Albany Street, Room L 603, Boston, MA 02118 2526, USA
    J Mol Neurosci 24:425-42. 2004
    ..These models are very helpful in elucidating the pathophysiology of PD but do not completely recapitulate the disease process. The relationship between these transgenic models and PD is a subject of intense investigation...
  18. ncbi Iron and Parkinson's disease
    Benjamin Wolozin
    Department of Pharmacology, Loyola University Medical Center, Maywood, Illinois, USA
    Neuroscientist 8:22-32. 2002
    ..Recent studies suggest that an additional mechanism by which iron might contribute to PD is by inducing aggregation of the alpha-synuclein, which is a protein that accumulates in Lewy bodies in PD...
  19. ncbi Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients
    Hossein A Ghanbari
    Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106, USA
    Aging Cell 3:41-4. 2004
    ..Primary culture of human olfactory neurons will be useful in understanding the mechanism of oxidative damage in Alzheimer's disease and can even be utilized in developing therapeutic strategies...

Research Grants18

  1. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2001
    ..abstract_text> ..
  2. LRRK2 and Neurodegeneration
    Benjamin Wolozin; Fiscal Year: 2009
    ..elegans. This aim will elucidate whether wild type LRRK2 normally protects against pathophysiological changes associated with PD, and whether PD-related mutations in LRRK2 enhance these changes. ..
  3. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin L Wolozin; Fiscal Year: 2010
    ..Aim 3 will determine whether combined use of a mitochondrial complex II stimulant plus an apoptotic inhibitor or antioxidant protects neurons against degeneration in transgenic mice carrying the A53T alpha-synuclein transgene.. ..
  4. LRRK2 and Neurodegeneration
    Benjamin L Wolozin; Fiscal Year: 2010
    ..elegans. This aim will elucidate whether wild type LRRK2 normally protects against pathophysiological changes associated with PD, and whether PD-related mutations in LRRK2 enhance these changes. ..
  5. LRRK2 and Neurodegeneration
    Benjamin Wolozin; Fiscal Year: 2009
    ..elegans. This aim will elucidate whether wild type LRRK2 normally protects against pathophysiological changes associated with PD, and whether PD-related mutations in LRRK2 enhance these changes. ..
  6. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin Wolozin; Fiscal Year: 2009
    ..Aim 3 will determine whether combined use of a mitochondrial complex II stimulant plus an apoptotic inhibitor or antioxidant protects neurons against degeneration in transgenic mice carrying the A53T alpha-synuclein transgene.. ..
  7. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin Wolozin; Fiscal Year: 2007
    ..Aim 3 will determine whether combined use of a mitochondrial complex II stimulant plus an apoptotic inhibitor or antioxidant protects neurons against degeneration in transgenic mice carrying the A53T alpha-synuclein transgene.. ..
  8. Interaction Between Genes and the Mitochondria in Parkin
    Benjamin Wolozin; Fiscal Year: 2006
    ..Aim 3 will determine whether combined use of a mitochondrial complex II stimulant plus an apoptotic inhibitor or antioxidant protects neurons against degeneration in transgenic mice carrying the A53T alpha-synuclein transgene.. ..
  9. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2004
    ..abstract_text> ..
  10. Regulation of APP Processing by Presenilins
    Benjamin Wolozin; Fiscal Year: 2004
    ..Identification of mutant forms of presenilin that inhibit beta- amyloid production could lead to novel strategies for therapeutic intervention in Alzheimer's disease. ..
  11. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2003
    ..abstract_text> ..
  12. Regulation of APP Processing by Presenilins
    Benjamin Wolozin; Fiscal Year: 2003
    ..Identification of mutant forms of presenilin that inhibit beta- amyloid production could lead to novel strategies for therapeutic intervention in Alzheimer's disease. ..
  13. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2002
    ..abstract_text> ..
  14. Regulation of APP Processing by Presenilins
    Benjamin Wolozin; Fiscal Year: 2002
    ..Identification of mutant forms of presenilin that inhibit beta- amyloid production could lead to novel strategies for therapeutic intervention in Alzheimer's disease. ..
  15. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2001
    ..abstract_text> ..
  16. Regulation of APP Processing by Presenilins
    Benjamin Wolozin; Fiscal Year: 2001
    ..Identification of mutant forms of presenilin that inhibit beta- amyloid production could lead to novel strategies for therapeutic intervention in Alzheimer's disease. ..
  17. LRRK2 and Neurodegeneration
    Benjamin L Wolozin; Fiscal Year: 2010
    ..elegans. This aim will elucidate whether wild type LRRK2 normally protects against pathophysiological changes associated with PD, and whether PD-related mutations in LRRK2 enhance these changes. ..